Sarepta Therapeutics, Inc.

Equities

SRPT

US8036071004

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:00 2024-03-28 pm EDT 5-day change 1st Jan Change
129.5 USD -0.59% Intraday chart for Sarepta Therapeutics, Inc. +2.68% +34.25%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
FDA greenlights Italfarmaco's drug for rare muscular dystrophy RE
Transcript : Sarepta Therapeutics, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 03:05 PM
Sarepta Therapeutics Insider Sold Shares Worth $1,848,795, According to a Recent SEC Filing MT
Transcript : Sarepta Therapeutics, Inc. Presents at Leerink Partners Global Biopharma Conference 2024, Mar-11-2024 10:00 AM
Sarepta Therapeutics Insider Sold Shares Worth $385,480, According to a Recent SEC Filing MT
UBS Raises Sarepta Therapeutics Price Target to $167 From $164, Maintains Buy Rating MT
Sarepta Therapeutics' Regulatory Drug Review Underpins Prospects for Rally, RBC Says MT
Deutsche Bank Cuts Sarepta Therapeutics Price Target to $156 From $158, Maintains Buy Rating MT
Needham Cuts Price Target on Sarepta Therapeutics to $166 From $169, Maintains Buy Rating MT
RBC Boosts Price Target on Sarepta Therapeutics to $157 From $151, Keeps Outperform Rating MT
Sarepta Therapeutics Swings to Q4 Profit, Revenue Increases; Shares Rise After Market MT
Transcript : Sarepta Therapeutics, Inc., Q4 2023 Earnings Call, Feb 28, 2024
Earnings Flash (SRPT) SAREPTA THERAPEUTICS Posts Q4 Revenue $396.8M, vs. Street Est of $386.2M MT
Earnings Flash (SRPT) SAREPTA THERAPEUTICS Posts Q4 EPS $0.82, vs. Street Est of $0.37 MT
Sarepta Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Sarepta Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Prices for new US drugs rose 35% in 2023, more than the previous year RE
Sector Update: Health Care Stocks Higher Late Afternoon MT
Sector Update: Health Care Stocks Advance Friday Afternoon MT
Sector Update: Health Care MT
Sarepta Therapeutics Says FDA Grants Priority Review to Efficacy Supplement to Elevidys' BLA to Expand its Indication MT
Exchange-Traded Funds Higher, Equity Futures Mixed Ahead of Inflation Data MT
US FDA to review Sarepta's Duchenne gene therapy for traditional approval RE
Sarepta Therapeutics Announces U.S. FDA Acceptance of an Efficacy Supplement to Expand the Elevidys Indication CI
Wegovy packing supplier Catalent lays off 300 workers RE
Chart Sarepta Therapeutics, Inc.
More charts
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on helping patients through the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. It has developed multiple approved products for the treatment of Duchenne muscular dystrophy (Duchenne) and is developing potential therapeutic candidates for a range of diseases and disorders, including Duchenne, Limb-girdle muscular dystrophies (LGMDs) and other neuromuscular and central nervous system (CNS) related disorders. It has developed and commercialized four approved products for the treatment of Duchenne: EXONDYS 51 (eteplirsen), Injection (EXONDYS 51), VYONDYS 53 (golodirsen) Injection (VYONDYS 53), AMONDYS 45 (casimersen) Injection (AMONDYS 45), and ELEVIDYS. Its pipeline includes approximately 40 programs at various stages of discovery, pre-clinical and clinical development.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
129.5 USD
Average target price
164.3 USD
Spread / Average Target
+26.93%
Consensus
  1. Stock
  2. Equities
  3. Stock Sarepta Therapeutics, Inc. - Nasdaq
  4. News Sarepta Therapeutics, Inc.
  5. Sarepta Therapeutics Prices Offering of $1 Billion of Convertible Notes